Toxic Erythema of Chemotherapy: Clinical Insights and Management

In a recent session on toxic erythema of chemotherapy (tech), Dr. Krista Yarte, a dermatologist at Beth Israel Deaconess Medical Center, discussed the significance of managing skin toxicities in oncology patients. Approximately 75% of cancer patients experience cutaneous side effects from treatment, and careful identification and management are crucial to maintain their chemotherapy regimen. Toxic erythema, first coined in 2008, encompasses a range of non-allergic skin reactions that occur within weeks of chemotherapy. Dr. Yarte emphasized the pathophysiology of tech, which is distinct from hypersensitivity reactions, and results from direct cytotoxic effects on skin cells rather than immune responses. Key features of tech include painful erythema predominantly found in areas rich in eccrine glands, such as palms, soles, and intertriginous skin. Common chemotherapy agents involved in tech include antimetabolites, alkylating agents, and taxanes. The session reviewed subtypes of tech, such as hand-foot syndrome and neutrophilic eccrine hidradenitis, leading to painful eruptions often affecting patients' daily lives. Notably, patients who develop skin toxicity may experience improved cancer outcomes, leading to ongoing research in this area. Finally, Dr. Yarte highlighted the need for continuous education amongst oncologists and dermatologists to closely monitor and manage these skin reactions.